These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 26087957)

  • 1. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
    Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
    Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
    Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
    J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.
    Kuenzi BM; Remsing Rix LL; Kinose F; Kroeger JL; Lancet JE; Padron E; Rix U
    Sci Rep; 2019 Jan; 9(1):606. PubMed ID: 30679640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
    Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
    J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
    Yakymiv Y; Augeri S; Bracci C; Marchisio S; Aydin S; D'Ardia S; Massaia M; Ferrero E; Ortolan E; Funaro A
    Sci Rep; 2021 Oct; 11(1):21230. PubMed ID: 34707185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
    Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
    J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.
    Merhi F; Tang R; Piedfer M; Mathieu J; Bombarda I; Zaher M; Kolb JP; Billard C; Bauvois B
    PLoS One; 2011; 6(10):e25963. PubMed ID: 21998731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Effects and Regulatory Mechanism of Targeting CXC Chemokine Receptor 1/2 Combined with Ara-C on the Malignant Biological Behaviors of U937 Cells of Acute Myeloid Leukemia].
    Liu YQ; Shen JZ; Yin Y; Chen YT; Yang H; Tang HW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):364-376. PubMed ID: 37096507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells.
    Chiou JT; Chang LS
    Biochem Pharmacol; 2024 Jun; 224():116242. PubMed ID: 38679209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
    Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
    Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
    Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
    Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.